CSIMarket Company Name, Ticker, Competitors, else..
 

Rvl Pharmaceuticals Plc  (NASDAQ: RVLP)

Rvl Pharmaceuticals Plc's

Competitiveness



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 

RVLP Sales vs. its Competitors Q2 2023


Comparing the current results to its competitors, Rvl Pharmaceuticals Plc reported Revenue decrease in the 2 quarter 2023 year on year by -13.45 %, faster than the overall decrease of Rvl Pharmaceuticals Plc's competitors by -4.54 %, recorded in the same quarter.

• List of RVLP Competitors





Revenue Growth Comparisons




Net Income Comparison

Rvl Pharmaceuticals Plc, despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 136.89 %

<<  RVLP Stock Performance Comparisons





  

Overall company Market Share Q2 2023
Overall company, revenue fell by -13.45 % and company lost market share, to approximately 0.05 %.




<<  More on RVLP Market Share.
 
*Market share is calculated based on total revenue.





Publicly Traded Peers of Rvl Pharmaceuticals Plc




Ardelyx inc
Share Performance



-2.88%
Over The Past 5 Days
Ardelyx inc
Profile

Ardelyx Inc is a biopharmaceutical company that focuses on the development of novel, minimally-absorbed small molecules to treat gastrointestinal diseases. Their business model revolves around identifying specific needs within the gastrointestinal field and leveraging their research and development capabilities to create innovative therapeutic solutions. By partnering with other pharmaceutical companies and pursuing strategic collaborations, Ardelyx aims to bring its products to market and ultimately improve patient outcomes in the gastrointestinal space.

More about Ardelyx inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 912.122 mill. $ 427.679 mill. $ -58.060 mill.


Revance Therapeutics Inc
Share Performance



-37.18%
This Quarter
Revance Therapeutics Inc
Profile

Revance Therapeutics Inc is a biotechnology company that specializes in developing innovative treatments for medical aesthetic and therapeutic applications. Their business model revolves around researching and developing novel neuromodulator products primarily for the treatment of various aesthetic and therapeutic conditions. The company aims to license or commercialize their products and technologies to generate revenue and advance patient care in collaboration with partners.

More about Revance Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 380.377 mill. $ 247.003 mill. $ -1.629 mill.


Lifecore Biomedical Inc
Share Performance



-45.21%
One Year
Lifecore Biomedical Inc
Profile

Lifecore Biomedical is a contract development and manufacturing organization (CDMO) specializing in the development and aseptic manufacturing of sterile injectable pharmaceuticals.

More about Lifecore Biomedical Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 163.027 mill. $ 125.080 mill. $ -45.986 mill.


Evo Transportation and Energy Services Inc
Share Performance



0.00%
30 Days
Evo Transportation and Energy Services Inc
Profile

Evo Transportation and Energy Services Inc operates as a provider of energy services for the transportation industry. Their business model involves offering a range of solutions and technologies to help fleet operators transition to environmentally friendly and sustainable practices. This includes providing electric vehicle charging infrastructure, mobile energy storage, and related support services.

More about Evo Transportation and Energy Services Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,888.704 mill. $ 309.763 mill. $ -18.226 mill.


Evolus Inc
Share Performance



+1.91%
Over The Past 5 Days
Evolus Inc
Profile

Evolus Inc is a pharmaceutical company that operates in the field of aesthetics, with a primary focus on developing and commercializing minimally invasive treatments for patients. Their business model revolves around researching and developing innovative neurotoxin products to address various facial aesthetic concerns. The company aims to bring their products to market through strategic partnerships with healthcare professionals and providers, ensuring widespread accessibility and utilization.

More about Evolus Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 589.939 mill. $ 302.349 mill. $ -43.423 mill.

10 more competitors available

Sign in to see all competitors

Sign In Create Free Account

Sources: Rvl Pharmaceuticals Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Rvl Pharmaceuticals Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.